Home › Compare › YZOFF vs ABBV
YZOFF yields 3.66% · ABBV yields 3.06%● Live data
📍 YZOFF pulled ahead of the other in Year 8
Combined, YZOFF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of YZOFF + ABBV for your $10,000?
Yangtze Optical Fibre And Cable Joint Stock Limited Company researchs, develops, produces, and sells optical fiber and cable products in the People's Republic of China and internationally. The company operates in two segments, Optical Fibres and Optical Fibre Preforms, and Optical Fibre Cables segments. It also provides copper wire and related products; integrated wiring systems; technical development consulting services for computer hardware and software and ancillary equipment; and vapor and chemical raw materials. In addition, the company imports, exports, and sells submarine cables, optical cables, and other power cables and their accessories, as well as trades in raw materials; and installs cables, accessories, and systems related to various submarine projects. Further, it designs, produces, and sells optical communication equipment and electrical products, as well as provides integrated services in communication, computer, intelligent building, weak current system, and software development. Additionally, the company engages in research and promotion of medical materials, as well as provides general contracting engineering services. Yangtze Optical Fibre And Cable Joint Stock Limited Company was founded in 1988 and is headquartered in Wuhan, the People's Republic of China.
Full YZOFF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.